What was studied?
FLOW randomized 3,533 participants with type 2 diabetes and chronic kidney disease to semaglutide or placebo. The primary outcome combined major kidney events with kidney-related or cardiovascular death.
What did the researchers report?
The primary outcome occurred less often with semaglutide. The trial stopped early following a prespecified interim analysis, with median follow-up of 3.4 years.
What are the limits?
The result is specific to participants meeting the kidney-function and diabetes criteria. A composite outcome includes different events; it should not be read as proof of reversing kidney disease or as evidence for catalog products.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.